Clinical trialNCT04434040RecruitingPhase 2Interventional

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

SponsorDana-Farber Cancer InstituteEnrollment40Breast CancerCirculating Tumor DNAResidual CancerTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elizabeth A Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California San Francisco
San Francisco, California, United States
Jo Chien, MD
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Withdrawn
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois, United States
Withdrawn
University of Chicago Medical Center for Advanced Care Orland Park
Orland Park, Illinois, United States
Withdrawn
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Elizabeth A Mittendorf, MD, PHD
Recruiting
University of Pennsylvania-Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Angela DeMichele, MD
Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Vandana Abramson, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Sacituzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 2 Jul 2020
Primary completion: 30 Dec 2026
Completion: 30 Dec 2027
Last update posted: 4 May 2026
Registered enrollment: 40
Registry id: NCT04434040

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.